German Ophthalmological Society (DOG) Honors Uta Gehlsen, PhD, with Prestigious Scientific Award for Her Research on the Use of Semifluorinated Alkanes in Dry Eye Treatment
The German Ophthalmological Society (DOG) presented Uta Gehlsen, PhD, Ocular Surface Group, Department of Ophthalmology, University of Cologne, with the “Dry Eye and Blepharitis/MGD” Award for her research related to the use of a semifluorinated alkane (SFA F4H5) as a novel carrier for cyclosporine A for the topical treatment of dry eye disease (DED).1
The DOG Awards recognize scientific and academic excellence, the advancement of young researchers, interdisciplinary and internationality in the field of ophthalmology. Sponsored by Optima Pharmazeutische GmbH, the award was presented on Saturday, September 30, 2017 during the 115th DOG Congress in Berlin.
Dr. Gehlsen’s research, which was published in Graefe’s Archive for Clinical and Experimental Ophthalmology in January 2017, found that a cyclosporine A formulation using F4H5 as its vehicle (CyclASol®, Novaliq) was equally effective but had a significantly faster therapeutic response in reducing the signs of DED compared to a commercially available treatment in an experimental mouse model.
Topical cyclosporine is a well-established medication used to treat signs of DED. It has anti-inflammatory effects and prevents T-cell activation. Clinical studies have shown that it is effective in reducing corneal staining and/or increasing tear production. Cyclosporine is also a highly lipophilic substance typically formulated as an emulsion which often causes adverse side effects with burning and stinging sensations due to the involved surfactants. The premise of the study was to learn whether a new SFA drug delivery system may improve efficacy or tolerability of cyclosporine.
“It is an honor to have been recognized by the DOG for our work in the area of SFA drug delivery technology and dry eye disease,” said Dr. Gehlsen. “Using the desiccating-stress dry-eye mouse model enables us to perform highly standardized pre-clinical in-vivo testing of topical therapies for inflammatory dry eye disease. Our experimental studies with several cyclosporine formulations hereby demonstrated a significantly faster and equally effective topical treatment effect for CyclASol® compared to other commercially available products. I am very pleased that our experimental results for CyclASol® have now been confirmed in the CYS-002 multicenter US clinical trial and hopefully will be soon available to treat patients suffering from dry eye disease.”
In this pre-clinical study, 0.05% cyclosporine dissolved in the F4H5 (CyclASol®) was found to be highly effective in reducing corneal staining and increasing tear production. Compared to the commercially available therapy comparator group, CyclASol® demonstrated at least a comparable therapeutic effect, but with a significantly faster response. Notably, early therapy with CyclASol® protected mice from developing dry eye, whereas all other study groups showed a significant increase of staining compared to baseline. CyclASol® also was the only studied treatment that demonstrated a prophylactic effect.
“On behalf of Novaliq, I congratulate Dr. Gehlsen for being presented with this award by the prestigious German Ophthalmological Society,” said Christian Roesky, PhD, managing director and CEO, Novaliq GmbH. “Through their research, we are better able to understand the many benefits of the SFA vehicle when added to traditionally insoluble or unstable drugs such as cyclosporine. Equipped with this knowledge, Novaliq has developed a very exciting and robust dry eye pipeline that has the potential to address significant unmet medical needs.”
About CyclASol ® – CyclASol® is a clear, preservative-free ophthalmic solution of cyclosporine A formulated using Novaliq’s proprietary EyeSol® drug delivery technology.
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol ® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. Novaliq’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol ® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.
About German Ophthalmological Society (DOG)—The DOG is the medical scientific association of ophthalmology in Germany and besides the oldest ophthalmological association in the world. It unites more than 7,000 ophthalmologists in hospitals, medical and research units. One of its main scopes is to advance scientific progress in ophthalmology and to transfer acknowledged findings into the daily routine in clinics and physicians’ practices.
1. Gehlsen U, Braun T, Notara M, Krösser S, Steven P; A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye; Graefes Arch Clin Exp Ophthalmol 2017; 255(4): 767-775
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Quanergy Announces Availability of Power Over Ethernet for M8 LiDAR Sensor26.9.2018 17:09 | Tiedote
Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, today announced the availability of its M8 LiDAR sensor with Power over Ethernet (PoE+). This new connector interface, designed specifically for the security market, allows the sensor to be easily installed and integrated with new or existing security systems, without costly custom wiring to power the LiDAR sensor. Surveillance systems leverage PoE to transmit power and data across the sensor and system. The IEEE 802.3at (PoE+) specification provides more power to PoE-powered devices and allows for a broader range of devices to be easily integrated into a network via standard Ethernet cable. The release of the M8 with PoE+ allows for a simpler, more flexible installation of LiDAR-based security systems. Its plug-and-play usability permits customers to make use of their existing security infrastructure when upgrading to a LiDAR-based security solution, leading
Moody’s Analytics and Thomson Reuters Partner on IFRS9 SPPI Solution for Fixed-Income Investors26.9.2018 16:11 | Tiedote
Moody’s Analytics, a leading provider of financial intelligence and analytics, partners with Thomson Reuters Financial and Risk business to offer a classification solution for conducting the Solely for Payment of Principal and Interest (SPPI) tests required under the IFRS9 accounting standard. The solution allows fixed-income investors to automate SPPI tests for securities in their portfolios by providing data on over 1.2 million corporate, government, and structured securities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005527/en/ “We are pleased to partner with Thomson Reuters to bring fixed-income investors more comprehensive coverage of all asset classes in a single transparent and auditable solution,” said Luis Amador, Managing Director at Moody’s Analytics. In addition to securities held in clients’ portfolios, the solution permits users to conduct additional due diligence on bonds that have not been
Rimini Street Honored with Multiple Award Wins for Customer Service Excellence26.9.2018 16:00 | Tiedote
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has been honored with multiple award wins from three prestigious award groups for the Company’s unwavering dedication to providing outstanding service delivery to clients around the world. Rimini Street won a total of thirteen awards across three prominent award organizations – Stevie® International Business Awards, Globee® Awards and Customer Sales and Service (CSS) World Awards® – in categories for Customer Service Department of the Year, Customer Service Leadership of the Year, Customer Service Team of the Year, Customer Service Executive of the Year, and Company of the Year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005217/en/ Rimini Street Honored with Multiple Award Wins for Customer Service Excellence (Photo
SailPoint Named a Leader in Identity Management and Governance by Independent Research Firm26.9.2018 16:00 | Tiedote
SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance, has been named a leader in “The Forrester Wave™: Identity Management and Governance, Q3 2018,” by Forrester Research, Inc. After conducting an exhaustive evaluation of vendors and their products in the identity management and governance (IMG) market, Forrester gave SailPoint the top ranking in all three evaluation categories: Strategy, Current Offering and Market Presence. In the Current Offering category, SailPoint’s Open Identity Platform, which includes IdentityIQ, IdentityNow, SecurityIQ and IdentityAI, received the highest possible score for 10 of the 12 criteria, including for the user account provisioning, identity analytics, and deployment options criterion. According to Forrester, in order to score a 5.0 out of a possible 5.0 points in the deployment options criterion, a vendor must support “an exceptional amount of deployment options for its IMG solution, including but not limite
Synteract Adds to Leadership Team with Rare and Orphan Disease Experts Lisa Dilworth and Elisabeth Schrader26.9.2018 16:00 | Tiedote
Synteract, an innovative contract research organization (CRO) enabling biopharma companies to bring new medicines to market, has added two experienced members to enhance its Rare and Orphan Diseases Center of Development. Lisa Dilworth joins as vice president, rare and orphan diseases, and Elisabeth Schrader as executive director, program strategy, pediatrics and rare diseases. Synteract has a long history of providing rare and orphan clinical trial expertise, across all phases of drug development, with more than 136 trials performed in the last five years across 50+ indications. It specializes in studies for diseases that affect a small portion of the population, where it applies its considerable operational acumen to studies that have never been done before. “Studies for diseases that affect a small portion of the population have been a mainstay of Synteract’s for many years. With extensive and varied backgrounds in rare and orphan drug development, Lisa and Elisabeth are excellent a
SimScale Releases Major User Interface Update for a Better Simulation Experience in the Cloud26.9.2018 15:34 | Tiedote
SimScale, the provider of the world’s first production-ready SaaS application for engineering simulation, announced today the release of their new workbench. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005496/en/ Conjugate heat transfer simulation of an electronics enclosure with SimScale (Graphic: Business Wire) SimScale Workbench 2.0 was built entirely from scratch on the latest, state-of-the-art technology stack, with the goal of drastically improving user productivity by decreasing loading time and increasing interaction speed. The SimScale web-based CAE platform is now as fast and interactive as a desktop application while taking advantage of the unlimited computing power of the cloud. Furthermore, the new solution stack sets the stage for major new features that are already in development and will be released soon. “Right from the start I love it! Well done. This is a really nice improvement,” said Ben Lewis,
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme